Refine by
Therapeutic Antibody Articles & Analysis
47 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. ...
Its end-to-end rare disease therapy development solutions cover a full package of therapeutic development services, which include small molecule, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. ...
Another hot topic during the festival was the growing interest in single domain antibodies—also known as sdAbs. Unlike traditional antibodies, sdAbs are much smaller, making them more versatile and efficient for use in therapeutics, imaging, and diagnostics. ...
The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost therapeutic efficacy while reducing unwanted side effects. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
Precision Targeting: The technology allows for the precise targeting of disease-related molecules by understanding the intricate interactions between antibodies and antigens, minimizing off-target effects and improving therapeutic outcomes. 3. ...
Animal Extracts: The company takes pride in its assortment of Animal Extracts, responsibly sourced and invaluable in various research, diagnostic, and therapeutic applications. From antibodies to enzymes, these extracts play a pivotal role in advancing scientific and medical frontiers, underscoring Creative Enzymes' commitment to impactful biotechnology. 3. ...
(NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning model developed to ...
(Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of ...
Although it can be argued that therapeutic antibody development relies on semi-random search-and-selection methods, such as phage display and biopanning, there is an increasingly important role played by structure-based design. ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, ...
Jake Kurtis, identified the parasite protein PfGARP as a target of human antibodies which kill up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death – this discovery forms the basis of Ocean Biomedical’s lipid encapsulated mRNA-based vaccine and therapeutic monoclonal antibodies. ...
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. ...
Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream supply of APIs, antibodies, enzymes, therapeutic proteins, etc. BOC Sciences, featured with a comprehensive fermentation platform, is able to lift them out of the plight by culturing diverse microbial strains (usually fungi and ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
About Scancell Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications, development of a vaccine for COVID-19 and a growing portfolio of novel anti-TaG monoclonal antibodies. ImmunoBody® vaccines target dendritic cells and ...
ByScancell
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic ...
The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates using Araris peptide linkers for site-specific bioconjugation,” will be given on March 30, 2022, at 2:15 p.m. ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American ...
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates Total potential deal value of up to $586 million, plus royalties on commercial sales Synaffix ...